Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aclaris Therapeutics, Inc. - Common Stock
(NQ:
ACRS
)
3.505
-0.195 (-5.27%)
Delayed Quote
Updated: 1:48 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aclaris Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 07, 2024
ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Via
FinancialNewsMedia
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
↗
March 06, 2024
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Aclaris Therapeutics: Q4 Earnings Insights
↗
February 27, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
↗
January 11, 2024
Via
Benzinga
Breaking Down Aclaris Therapeutics: 6 Analysts Share Their Views
↗
December 18, 2023
Via
Benzinga
Aclaris Therapeutics Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
↗
December 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Aclaris Therapeutics
↗
November 14, 2023
Via
Benzinga
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
↗
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
January 22, 2024
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...
Via
Benzinga
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
↗
January 22, 2024
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
January 16, 2024
Via
Benzinga
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
↗
January 16, 2024
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris...
Via
Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
↗
January 10, 2024
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
Crude Oil Falls 1%; Amarin Shares Spike Higher
↗
January 10, 2024
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.29% to 37,633.43 while the NASDAQ rose 0.72% to 14,965.31. The...
Via
Benzinga
Topics
Stocks
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
January 10, 2024
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
January 10, 2024
Via
Benzinga
Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
↗
January 10, 2024
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded up 0.17% to 37,588.15 while the NASDAQ rose 0.34% to 14,908.42. The S&P...
Via
Benzinga
Topics
Stocks
Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
↗
January 10, 2024
Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
Dow Surges 100 Points; PriceSmart Earnings Top Views
↗
January 10, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 37,627.83 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 10, 2024
Via
Benzinga
Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study
↗
December 20, 2023
Aclaris Therapeutics Inc (NASDAQ: ACRS) announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed
Via
Benzinga
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
↗
December 06, 2023
Shares of SentinelOne, Inc. (NYSE: S) rose sharply in pre-market trading after the company reported stronger-than-expected results for its third quarter and raised its annual revenue outlook.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 14, 2023
Via
Benzinga
Crude Oil Gains Over 1%; US Budget Deficit Narrows For October
↗
November 13, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 while the NASDAQ fell 0.11% to 13,783.41. The S&P 500...
Via
Benzinga
Topics
Stocks
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 13, 2023
Via
Benzinga
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
↗
November 13, 2023
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500...
Via
Benzinga
Topics
Stocks
Why Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today?
↗
November 13, 2023
Aclaris Therapeutics Inc (NASDAQ: ACRS) shares plunged after the company released topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
